{"title":"New Mechanisms of DNA Repair Defects in Fused in Sarcoma-Associated Neurodegeneration: Stage Set for DNA Repair-Based Therapeutics?","authors":"Haibo Wang, Muralidhar L Hegde","doi":"10.1177/1179069519856358","DOIUrl":"https://doi.org/10.1177/1179069519856358","url":null,"abstract":"<p><p>Genome damage and defective DNA repair are etiologically linked to several neurodegenerative disorders, including fused in sarcoma (FUS)-associated amyotrophic lateral sclerosis (ALS). However, the underlying mechanisms remain enigmatic, which is a roadblock for exploiting genome repair-targeted therapies. Our recent studies identified defects in DNA nick ligation and oxidative damage repair caused by mutations in the RNA/DNA-binding protein FUS in familial ALS patients. In healthy neurons, FUS protects the genome by facilitating PARP1-dependent recruitment of XRCC1/DNA Ligase IIIα (LigIII) to oxidized genome sites and activating LigIII via direct interaction. This is a critical step in the repair of oxidative genome damage, a foremost challenge for postmitotic neurons due to their high oxygen consumption. We discovered that mutant FUS significantly inhibited the recruitment of XRCC1/LigIII to DNA strand breaks, causing defects in DNA ligation during the repair of oxidative DNA damage, which contributed to neurodegeneration. While the FUS loss of function was responsible for the repair defects, increased oxidative genome damage due to mutant FUS aggregation could exacerbate the phenomenon. We highlight how these new molecular insights into previously undescribed DNA repair defect linked to FUS-associated neurodegeneration could provide an important opportunity for exploring DNA repair-based therapeutic avenues.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519856358"},"PeriodicalIF":0.0,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179069519856358","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37344709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rev-erbs and Glia-Implications for Neurodegenerative Diseases.","authors":"Percy Griffin, Julie M Dimitry, Erik S Musiek","doi":"10.1177/1179069519853233","DOIUrl":"https://doi.org/10.1177/1179069519853233","url":null,"abstract":"<p><p>Recently, we described a role for the circadian clock protein and nuclear receptor Rev-erbα in regulating glial activation states in the brain. Deletion of Rev-erbα resulted in microglial as well as astrocytic activation, while a Rev-erbα agonist diminished the severity of lipopolysaccharide (LPS)-induced neuroinflammation. Concomitant with this glial activation is impaired neuronal health. These findings suggest that Rev-erb proteins may play critical roles in glial biology. Pertinent ideas such as the glial cell type of most importance, the translatability of these findings to human disease, and the effect of manipulating Rev-erbs in models of neurodegeneration, need to be explored further. In this commentary, we will address the potential role of Rev-erbs in neuroinflammation related to neurodegenerative diseases and speculate on Rev-erbs as potential therapeutic targets for these conditions.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519853233"},"PeriodicalIF":0.0,"publicationDate":"2019-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179069519853233","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37338550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dissecting Static and Dynamic Functional Connectivity: Example From the Autism Spectrum.","authors":"Tonya White, Vince D Calhoun","doi":"10.1177/1179069519851809","DOIUrl":"https://doi.org/10.1177/1179069519851809","url":null,"abstract":"<p><p>The ability to measure the intrinsic functional architecture of the brain has grown exponentially over the last 2 decades. Measures of intrinsic connectivity within the brain, typically measured using resting-state functional magnetic resonance imaging (MRI), have evolved from primarily \"static\" approaches, to include dynamic measures of functional connectivity. Measures of dynamic functional connectivity expand the assumptions to allow brain regions to have temporally different patterns of communication between different regions. That is, connections within the brain can differentially fire between different regions at different times, and these differences can be quantified. Applying approaches that measure the dynamic characteristics of functional brain connectivity have been fruitful in identifying differences during brain development and psychopathology. We provide a brief overview of static and dynamic measures of functional connectivity and illustrate the synergy in applying these approaches to identify both age-related differences in children and differences between typically developing children and children with autistic symptoms.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519851809"},"PeriodicalIF":0.0,"publicationDate":"2019-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179069519851809","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37338549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration.","authors":"Suzanne Jackowski","doi":"10.1177/1179069519851118","DOIUrl":"https://doi.org/10.1177/1179069519851118","url":null,"abstract":"<p><p>Multiple approaches to therapy have been proposed for the rare inherited neurodegenerative disease associated with mutations in the <i>PANK2</i> gene, called pantothenate-kinase-associated neurodegeneration (PKAN). Penetration of the blood-brain barrier for treatment of a central nervous system (CNS) disorder is a major challenge in drug discovery. Evaluation of the biochemistry and medicinal chemistry of the proposed therapies reveals potential liabilities among several compounds under consideration for clinical development.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519851118"},"PeriodicalIF":0.0,"publicationDate":"2019-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179069519851118","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37074541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Mechanism for the Development of Chronic Traumatic Encephalopathy From Persistent Traumatic Brain Injury.","authors":"Melissa Demock, Steven Kornguth","doi":"10.1177/1179069519849935","DOIUrl":"https://doi.org/10.1177/1179069519849935","url":null,"abstract":"<p><p>A mechanism that describes the progression of traumatic brain injury (TBI) to end-stage chronic traumatic encephalopathy (CTE) is offered in this article. This mechanism is based upon the observed increase in the concentration of both tau protein and of human leukocyte antigen (HLA) class I proteins; the HLA increase is expressed on the cell membrane of neural cells. These events follow the inflammatory responses caused by the repetitive TBI. Associated inflammatory changes include macrophage entry into the brain parenchyma from increased permeability of the blood-brain barrier (BBB) and microglial activation at the base of the sulci. The release of interferon gamma from the microglia and macrophages induces the marked increased expression of HLA class I proteins by the neural cells and subsequent redistribution of the tau proteins to the glial and neuronal surface. In those individuals with highly expressed HLA class I C, the high level of HLA binds tau protein electrostatically. The ionic region of HLA class I C (amino acid positions 50-90) binds to the oppositely charged ionic region of tau (amino acid positions 93-133). These interactions thereby shift the cellular localization of the tau and orient the tau spatially so that the cross-linking sites of tau (275-280 and 306-311) are aligned. This alignment facilitates the cross-linking of tau to form the intracellular and extracellular microfibrils of tau, the primary physiological characteristic of tauopathy. Following endocytosis of the membrane HLA/tau complex, these microfibrils accumulate and produce a tau-storage-like disease. Therefore, tauopathy is the secondary collateral process of brain injury, resulting from the substantial increase in tau and HLA expression on neural cells. This proposed mechanism suggests several potential targets for mitigating the clinical progression of TBI to CTE.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519849935"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179069519849935","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37074540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mosaic <i>APP</i> Gene Recombination in Alzheimer's Disease-What's Next?","authors":"Ming-Hsiang Lee, Jerold Chun","doi":"10.1177/1179069519849669","DOIUrl":"https://doi.org/10.1177/1179069519849669","url":null,"abstract":"<p><p>A first example of somatic gene recombination (SGR) within the human brain was recently reported, involving the well-known Alzheimer's disease (AD)-related gene amyloid precursor protein (<i>APP</i>). SGR was characterized by the creation of <i>APP</i> genomic complementary DNA (gencDNA) sequences that were identified in prefrontal cortical neurons from both normal and sporadic Alzheimer's disease (SAD) brains. Notably, SGR in SAD appeared to become dysregulated, producing many more numbers and forms of <i>APP</i> gencDNAs, including 11 single-nucleotide variations (SNVs) that are considered pathogenic <i>APP</i> mutations when they occur in families, yet are present mosaically among SAD neurons. <i>APP</i> gene transcription, reverse transcriptase (RT) activity, and DNA strand-breaks were shown to be three key factors required for <i>APP</i> gencDNA production. Many mechanistic details remain to be determined, particularly how <i>APP</i> gencDNAs are involved in AD initiation and progression. The possibility of reducing disease-related SGR through the use of RT inhibitors that are already FDA-approved for HIV and Hepatitis B treatment represents both a testable hypothesis for AD clinical trials and a genuine therapeutic option, where none currently exists, for AD patients.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519849669"},"PeriodicalIF":0.0,"publicationDate":"2019-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179069519849669","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37074537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Role of Body-Related Afferent Signals in Human Sense of Agency.","authors":"Maria Pyasik, Tiziano Furlanetto, Lorenzo Pia","doi":"10.1177/1179069519849907","DOIUrl":"https://doi.org/10.1177/1179069519849907","url":null,"abstract":"<p><p>At present, most of the neurocognitive models of human sense of agency (ie, \"this action is due to my own will\") have been traditionally rooted in a variety of internal efferent signals arising within the motor system. However, recent neuroscientific evidence has suggested that also the body-related afferent signals that subserve body ownership (ie, \"this body is mine\") might have a key role in this process. Accordingly, in the present review paper, we briefly examined the literature investigating how and to what extent body ownership contributes to building up human motor consciousness. Evidence suggests that, if required by the context, body ownership per se can act on agency attribution (ie, independently from efferent signals). Hence, a unitary and coherent subjective experience of willed actions (ie, \"this willed action is being realized by my own body\") requires both awareness of being an agent and of owning the body.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519849907"},"PeriodicalIF":0.0,"publicationDate":"2019-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179069519849907","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37074539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sex Differences in Animal Models of Traumatic Brain Injury.","authors":"Todd G Rubin, Michael L Lipton","doi":"10.1177/1179069519844020","DOIUrl":"https://doi.org/10.1177/1179069519844020","url":null,"abstract":"<p><p>Traumatic brain injury (TBI) is highly prevalent and there is currently no adequate treatment. Understanding the underlying mechanisms governing TBI and recovery remains an elusive goal. The heterogeneous nature of injury and individual's response to injury have made understanding risk and susceptibility to TBI of great importance. Epidemiologic studies have provided evidence of sex-dependent differences following TBI. However, preclinical models of injury have largely focused on adult male animals. Here, we review 50 studies that have investigated TBI in both sexes using animal models. Results from these studies are highly variable and model dependent, but largely show females to have a protective advantage in behavioral outcomes and pathology following TBI. Further research of both sexes using newer models that better recapitulate mild and repetitive TBI is needed to characterize the nature of sex-dependent injury and recovery, and ultimately identifies targets for enhanced recovery.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519844020"},"PeriodicalIF":0.0,"publicationDate":"2019-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179069519844020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37074538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Investigating the Subcortical Route to the Amygdala Across Species and in Disordered Fear Responses.","authors":"Jessica McFadyen","doi":"10.1177/1179069519846445","DOIUrl":"10.1177/1179069519846445","url":null,"abstract":"<p><p>Over the past few decades, evidence has come to light that there is a rapid subcortical shortcut that transmits visual information to the amygdala, effectively bypassing the visual cortex. This pathway purportedly runs from the superior colliculus to the amygdala via the pulvinar, and thus presents a methodological challenge to study noninvasively in the human brain. Here, we present our recent work where we reliably reconstructed the white matter structure and directional flow of neural signal along this pathway in over 600 healthy young adults. Critically, we found structure-function relationships for the pulvinar-amygdala connection, where people with greater fibre density had stronger functional neural coupling and were also better at recognising fearful facial expressions. These results tie together recent anatomical evidence from other visual primates with very recent optogenetic research on rodents demonstrating a functional role of this pathway in producing fear responses. Here, we discuss how this pathway might operate alongside other thalamo-cortical circuits (such as pulvinar to middle temporal area) and how its structure and function may change according to the sensory input it receives. This newly established circuit might play a potentially important role in autism and/or anxiety disorders.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519846445"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179069519846445","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37225641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alicia A Cutler, Theodore Eugene Ewachiw, Giulia A Corbet, Roy Parker, Brad B Olwin
{"title":"Myo-granules Connect Physiology and Pathophysiology.","authors":"Alicia A Cutler, Theodore Eugene Ewachiw, Giulia A Corbet, Roy Parker, Brad B Olwin","doi":"10.1177/1179069519842157","DOIUrl":"10.1177/1179069519842157","url":null,"abstract":"<p><p>A hallmark of many neuromuscular diseases including Alzheimer disease, inclusion body myositis, amyotrophic lateral sclerosis, frontotemporal lobar dementia, and ocular pharyngeal muscular dystrophy is large cytoplasmic aggregates containing the RNA-binding protein, TDP-43. Despite acceptance that cytoplasmic TDP-43 aggregation is pathological, cytoplasmic TDP-43 assemblies form in healthy regenerating muscle. These recently discovered ribonucleoprotein assemblies, termed myo-granules, form in healthy muscle following injury and are readily cleared as the myofibers mature. The formation and dissolution of myo-granules during normal muscle regeneration suggests that these amyloid-like oligomers may be functional and that perturbations in myo-granule kinetics or composition may promote pathological aggregation.</p>","PeriodicalId":15817,"journal":{"name":"Journal of Experimental Neuroscience","volume":"13 ","pages":"1179069519842157"},"PeriodicalIF":0.0,"publicationDate":"2019-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37183576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}